

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: Relay Medical Corp. (the "Issuer").

Trading Symbol: RELA

Number of Outstanding Listed Securities: 240,797,328

Date: May 4, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

### 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Relay Medical continues to develop and productize multiple products and projects concurrently as well as to consider strategic opportunities that are complimentary to current infrastructure assets. Relay is concurrently developing products within the Fionet Rapid Response Group ("FRR"), the HemoPalm platform and related In Vitro Diagnostics products, Pharmatrac and Osprey Device Networks Corp. (formerly Relay MedNet) as well as the initial development of partially owned subsidiary Glow Lifetech Ltd. In addition, the Company continues to support Glow in their Go Public efforts and on February 9, 2021 invested an additional \$600,000 to acquire 2 million shares, which brings its total equity position to 8.25 million shares.

On April 14, 2021, the Company announced together through their joint venture company, Fionet Rapid Response Group ("FRR"), the execution of an agreement with LifeLabs LP ("LifeLabs") to deploy the Fionet Platform for COVID-19 rapid testing and real-time tracking across Canada. Under the terms of the agreement, LifeLabs will provide the Fionet Platform in community-based settings at multiple sites across Canada, including airports, pop-up labs, and installations for small businesses. The Fionet Platform is integrated into LifeLabs' laboratory information system, ensuring seamless interoperability, as well as into LifeLabs' turnkey, end-to-end COVID-19 rapid diagnostic testing (RDT) program to support Canadians as they return to work.

On April 16, 2021, the Company announced together through their joint venture company, Fionet Rapid Response Group ("FRR") report on recent news related to the impact of COVID-19 vaccinations, emerging new variants and the continued need for widespread rapid testing solutions such as the Fionet Platform, for community-based COVID-19 testing. Difficulties in the gradual roll-out of vaccines and continued threat of novel variants across the globe means that widespread, affordable, and accurate diagnostic testing remains a critical component to the global COVID response. With deployment of vaccines occurring at varying rates around the world, communities are still at risk of the virus spreading and hotspots re-emerging, as such, testing will remain a vital tool for controlling the pandemic and safely opening up economies.

On April 26, 2021, the Company announced that Emerging Markets Consulting, LLC (EMC) has been retained to provide investor and public relations services. EMC specializes in helping small and mid-sized public companies establish brand awareness and increase market share to its customer base while improving visibility to the institutional and retail investment community.

On April 27, 2021, the Company, a shareholder in Glow Lifetech Corp., announced that Glow reported on submitting an application to Health Canada to obtain produce licenses for its Natural Health Product (NHP), ArtemiC™, which reported successful results from a COVID-19 Phase II clinical trial.

### 2. Provide a general overview and discussion of the activities of management.

Management continued to be involved in the development of its business as more specifically detailed in 1 above.

- 3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

Management continued to be involved in the development of its business through new products and services as more specifically detailed in 1 above.

- 4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None in the month of April 2021.

- 5. Report on any labour disputes and resolutions of those disputes if applicable.**

None in the month of April 2021.

- 6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None in the month of April 2021.

- 7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None in the month of April 2021.

- 8. Provide details of any securities issued and options or warrants granted.**

The Company issued 500,000 common shares relating to the exercise of 350,000 options and 150,000 warrants at an exercise price an exercise price of \$0.225 and \$0.30 respectively.

On April 9, 2021, the Company issued 588,524 common shares at a price of \$0.61 to certain consultants of the Company as compensation for consulting servcies performed on the Cybeat's acquisition.

- 9. Provide details of any loans to or by Related Persons.**

None in the month of April 2021.

**10. Provide details of any changes in directors, officers or committee members.**

None in the month of April 2021.

**11. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On March 12, 2020, the World Health Organization ("WHO") declared a global pandemic as a result of the COVID-19 virus. The impacts on global commerce are expected to be far reaching and, at this point, unknown. The global lock-down impacts have negatively impacted the economy as a whole and capital markets in Canada. The effects on the Company's operations have been minor to date but management continues to monitor and contingency plan.

On September 4 2020, Health Canada announced new steps towards gaining control over the COVID-19 pandemic by supporting community-based testing solutions: (1) it will support enhanced solutions for airport testing; (2) it invited potential solutions to be submitted for home testing; and (3) it authorized clinical trials for rapid diagnostics tests ("RDTs") which are fast, inexpensive test strips that can be used in locations outside of laboratories.

**Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 4, 2021.

Yoav Raiter

**Name of Director or Senior  
Officer**

*"Yoav Raiter"*  
**Signature**

Chief Executive Officer  
**Official Capacity**

<b>Issuer Details</b> Name of Issuer Relay Medical Corp.	For Month End April 30, 2021	Date of Report YY/MM/D 2021/05/04
Issuer Address 65 International Blvd. Suite 202		
City/Province/Postal Code Toronto, ON M9W 6L9	Issuer Fax No. 1-844-247-6633	Issuer Telephone No. 647-872-9982
Contact Name W. Clark Kent	Contact Position President	Contact Telephone No. 647-872-9982
Contact Email Address ckent@relaymedical.com	Web Site Address <a href="https://www.relaymedical.com/">https://www.relaymedical.com/</a>	